City of Hope

www.cityofhope.org

 

ASH 2022 Conference Coverage
F

ASH 2022 Understanding and Monitoring Resistance to Anti-CD38 and -BCMA Therapies

By ASH 2022 Conference Coverage FEATURING Flavia Pichiorri
By ASH 2022 Conference Coverage FEATURING Flavia Pichiorri
193 views
January 4, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Myeloma
11:43
City of Hope

Practical Perspectives on Recent CAR-T FDA Approvals in Myeloma

Feat. M. Janakiram
20:46
ASH 2022 Conference Coverage

ASH 2022 Understanding and Monitoring Resistance to Anti-CD38 and -B…

Feat. F. Pichiorri
07:29
City of Hope

ASCO 2021 Updated Phase 1 Results of Teclistamab, a B-Cell Maturatio…

Feat. A. Krishnan
18:44
City of Hope

The Promise of Immunotherapy and Newer Agents in Multiple Myeloma

Feat. A. Krishnan
17:58
City of Hope

Should Everyone Receive Monoclonal Antibodies at First Myeloma Relap…

Feat. J. Mikhael